{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:48:11Z","timestamp":1792453691520,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01189-w","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T09:52:56Z","timestamp":1740909176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["90Y-Transarterial Radioembolization Combined with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review"],"prefix":"10.1007","volume":"56","author":[{"given":"Sedighe","family":"Hosseini Shabanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Shobeiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Behnoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Haghshomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"issue":"3","key":"1189_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA: Cancer J Clin"},{"issue":"2","key":"1189_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hep.27745","volume":"62","author":"S Roayaie","year":"2015","unstructured":"Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62(2):440\u201351.","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"1189_CR3","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.3747\/co.27.7171","volume":"27","author":"L Cardarelli-Leite","year":"2020","unstructured":"Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, et al. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol. 2020;27(Suppl 3):S144\u201351.","journal-title":"Curr Oncol"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2014.00210","volume":"4","author":"M Cremonesi","year":"2014","unstructured":"Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210.","journal-title":"Front Oncol"},{"issue":"3","key":"1189_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"issue":"20","key":"1189_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"9","key":"1189_CR8","first-page":"e45385","volume":"15","author":"Y Kawamura","year":"2023","unstructured":"Kawamura Y, Akuta N, Fujiyama S, Suzuki F, Kumada H. Two cases of advanced hepatocellular carcinoma who responded well to the combination of durvalumab plus tremelimumab after disease progression during atezolizumab plus bevacizumab therapy under bevacizumab withdrawal. Cureus. 2023;15(9):e45385.","journal-title":"Cureus"},{"issue":"8","key":"1189_CR9","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"8","key":"1189_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1189_CR11","doi-asserted-by":"publisher","unstructured":"Lyu N, Kong Y, Li X, Mu L, Deng H, Chen H, et al. Ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical response during PD-1 therapy: a proof-of-concept study. Front Oncol. 2020:2088. https:\/\/doi.org\/10.3389\/fonc.2020.580241.","DOI":"10.3389\/fonc.2020.580241"},{"key":"1189_CR12","doi-asserted-by":"publisher","first-page":"v288","DOI":"10.1093\/annonc\/mdz247.076","volume":"30","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Cole T, Bengsch B, Tait P, Sayed AA, Abomeli F, et al. A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. Ann Oncol. 2019;30:v288.","journal-title":"Ann Oncol"},{"issue":"1","key":"1189_CR13","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.ijrobp.2019.06.279","volume":"105","author":"W Smith","year":"2019","unstructured":"Smith W, Law A, Hulkower M, McGee H, Schwartz M, Taouli B, et al. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(1):S207.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1189_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335\u201346.","journal-title":"Gut"},{"issue":"6","key":"1189_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1189_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687\u201395.","journal-title":"J Clin Investig"},{"issue":"7547","key":"1189_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"T-S Victor","year":"2015","unstructured":"Victor T-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"7","key":"1189_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s00270-015-1259-0","volume":"39","author":"A Ghodadra","year":"2016","unstructured":"Ghodadra A, Bhatt S, Camacho JC, Kim HS. Abscopal effects and yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2016;39(7):1076\u201380.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"49","key":"1189_CR19","doi-asserted-by":"publisher","first-page":"54415","DOI":"10.1021\/acsami.0c15679","volume":"12","author":"B Yu","year":"2020","unstructured":"Yu B, Zhang W, Kwak K, Choi H, Kim DH. Electric pulse responsive magnetic nanoclusters loaded with indoleamine 2,3-dioxygenase inhibitor for synergistic immuno-ablation cancer therapy. ACS Appl Mater Interfaces. 2020;12(49):54415\u201325.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"1189_CR20","doi-asserted-by":"publisher","first-page":"13115","DOI":"10.1021\/acsnano.0c04701","volume":"14","author":"B Choi","year":"2020","unstructured":"Choi B, Choi H, Yu B, Kim DH. Synergistic local combination of radiation and anti-programmed death ligand 1 immunotherapy using radiation-responsive splintery metallic nanocarriers. ACS Nano. 2020;14(10):13115\u201326.","journal-title":"ACS Nano"},{"issue":"52","key":"1189_CR21","doi-asserted-by":"publisher","first-page":"e1904378","DOI":"10.1002\/smll.201904378","volume":"15","author":"B Choi","year":"2019","unstructured":"Choi B, Jung H, Yu B, Choi H, Lee J, Kim DH. Sequential MR image-guided local immune checkpoint blockade cancer immunotherapy using ferumoxytol capped ultralarge pore mesoporous silica carriers after standard chemotherapy. Small. 2019;15(52):e1904378.","journal-title":"Small"},{"issue":"17","key":"1189_CR22","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379\u201388.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1189_CR23","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn G-O, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727\u201339.","journal-title":"Clin Cancer Res"},{"key":"1189_CR24","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"issue":"1","key":"1189_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14(1):45.","journal-title":"BMC Med Res Methodol"},{"key":"1189_CR26","doi-asserted-by":"publisher","unstructured":"Chang EWY, Tai DW-M, Koo S-L, Ng MC, Yeong JPS, Zhai WW, et al. A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: an immunological study of radioembolization in combination with anti-PD1 therapy in HCC. Am Soc Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.TPS542.","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS542"},{"key":"1189_CR27","doi-asserted-by":"publisher","first-page":"S825","DOI":"10.1016\/j.annonc.2021.08.167","volume":"32","author":"J Lee","year":"2021","unstructured":"Lee J, Tan S, Hennedige T, Loke K, Gogna A, Ng D, et al. 947P updated survival and secondary safety and efficacy analyses from CA 209\u2013678: a phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2021;32:S825.","journal-title":"Ann Oncol"},{"key":"1189_CR28","doi-asserted-by":"publisher","unstructured":"Tai WMD, Loke KSH, Gogna A, Tan SH, Ng DCE, Hennedige TP, et al. A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209\u2013678. Am Soc Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4590.","DOI":"10.1200\/JCO.2020.38.15_suppl.4590"},{"issue":"5","key":"1189_CR29","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1016\/S0168-8278(23)00646-3","volume":"77","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim HC, et al. Radioembolization with yttrium-90 glass microspheres in combination with durvalumab in locally advanced unresectable hepatocellular carcinoma. Hepatology. 2023;77(5):E141\u20132.","journal-title":"Hepatology"},{"key":"1189_CR30","doi-asserted-by":"publisher","unstructured":"McRee AJ, Helft PR, Harris WP, Sanoff HK, Johnson M, Yu M, et al. A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function. Am Soc Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.422.","DOI":"10.1200\/JCO.2022.40.4_suppl.422"},{"key":"1189_CR31","first-page":"S189","volume":"76","author":"Y Hui Yeo","year":"2022","unstructured":"Hui Yeo Y, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub WS, et al. Combined transarterial radioembolization and immunotherapy versus immunotherapy alone for advanced hepatocellular carcinoma. Hepatology. 2022;76:S189\u201390.","journal-title":"Hepatology"},{"issue":"3","key":"1189_CR32","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/j.jvir.2018.12.517","volume":"30","author":"C Zhan","year":"2019","unstructured":"Zhan C, Ruohoniemi D, Kulkarni K, Martirosyan K, Welling T, Gu P, et al. 03: 54 PM Abstract No. 437 Safety and toxicity of concurrent Y90 radioembolization and checkpoint-inhibitor immunotherapy. J Vasc Interv Radiol. 2019;30(3):S191\u20132.","journal-title":"J Vasc Interv Radiol"},{"key":"1189_CR33","doi-asserted-by":"publisher","unstructured":"Fenton SE, Kircher SM, Mulcahy MF, Mahalingam D, Salem R, Lewandowski R, et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (yttrium-90) in patients with advanced hepatocellular cancer. Wolters Kluwer Health. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e16183.","DOI":"10.1200\/JCO.2021.39.15_suppl.e16183"},{"issue":"3","key":"1189_CR34","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jvir.2022.12.177","volume":"34","author":"K Menon","year":"2023","unstructured":"Menon K, Korff R, Kim E, Bishay V, Fischman A, Nowakowski F, et al. Abstract No. 126 Radioembolization prior to checkpoint inhibitor immunotherapy versus radioembolization post checkpoint inhibitor immunotherapy for the treatment of intermediate and advanced stage hepatocellular carcinoma. J Vasc Interv Radiol. 2023;34(3):S59.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1189_CR35","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jvir.2022.12.122","volume":"34","author":"R Korff","year":"2023","unstructured":"Korff R, Menon K, Kim E, Bishay V, Fischman A, Nowakowski F, et al. Abstract No. 76 Radioembolization plus immune checkpoint inhibitor therapy compared with radioembolization plus tyrosine kinase inhibitor therapy for the treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2023;34(3):S36\u20137.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1189_CR36","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1025\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1189_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31(1):25\u201334.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"1189_CR38","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jvir.2020.07.009","volume":"31","author":"B Marinelli","year":"2020","unstructured":"Marinelli B, Cedillo M, Pasik SD, Charles D, Murthy S, Patel RS, et al. Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients. J Vasc Interv Radiol. 2020;31(11):1729-38.e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"18","key":"1189_CR39","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","volume":"29","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim HC, et al. A phase I\/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29(18):3650\u20138.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1189_CR40","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","volume":"118","author":"YH Yeo","year":"2023","unstructured":"Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, et al. Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma. Am J Gastroenterol. 2023;118(12):2201\u201311.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1189_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, et al. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma. Oncologist. 2024;29(3):270-e413.","journal-title":"Oncologist"},{"issue":"5","key":"1189_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2024.02.004","volume":"35","author":"K Garcia-Reyes","year":"2024","unstructured":"Garcia-Reyes K, Gottlieb RA, Menon KM, Bishay V, Patel R, Patel R, et al. Radioembolization plus immune checkpoint inhibitor therapy compared with radioembolization plus tyrosine kinase inhibitor therapy for the treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2024;35(5):722-30.e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1189_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","volume":"356","author":"S Siva","year":"2015","unstructured":"Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82\u201390.","journal-title":"Cancer Lett"},{"issue":"6","key":"1189_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1189_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1189_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/gut.43.4.575","volume":"43","author":"K Ohba","year":"1998","unstructured":"Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998;43(4):575\u20137.","journal-title":"Gut"},{"issue":"1","key":"1189_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"1189_CR48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288\u2013306.","journal-title":"J Hepatol"},{"issue":"19","key":"1189_CR49","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific Patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1189_CR50","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1189_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"10088","key":"1189_CR52","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"key":"1189_CR53","doi-asserted-by":"publisher","unstructured":"Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, et al. Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2021-326869.","DOI":"10.1136\/gutjnl-2021-326869"},{"issue":"1","key":"1189_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52\u201364.","journal-title":"Gastroenterology"},{"issue":"5","key":"1189_CR55","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE, Scherag A, M\u00fcller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology"},{"issue":"5","key":"1189_CR56","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"},{"issue":"2","key":"1189_CR57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65(2):264\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"1189_CR58","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jclinepi.2010.11.021","volume":"64","author":"D Atkins","year":"2011","unstructured":"Atkins D, Chang SM, Gartlehner G, Buckley DI, Whitlock EP, Berliner E, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64(11):1198\u2013207.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1189_CR59","first-page":"216","volume":"38","author":"K Ramdhani","year":"2023","unstructured":"Ramdhani K, Smits ML, Lam MG, Braat AJ. Combining selective internal radiation therapy with immunotherapy in treating hepatocellular carcinoma and hepatic colorectal metastases: a systematic review. Cancer Biother Radiopharm. 2023;38(4):216\u201324.","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"1189_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","volume":"56","author":"B Sangro","year":"2012","unstructured":"Sangro B, I\u00f1arrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464\u201373.","journal-title":"J Hepatol"},{"issue":"9","key":"1189_CR61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrclinonc.2014.122","volume":"11","author":"A Forner","year":"2014","unstructured":"Forner A, Gilabert M, Bruix J, Raoul J-L. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11(9):525\u201335.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1189_CR62","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3748\/wjg.v21.i21.6518","volume":"21","author":"R Sacco","year":"2015","unstructured":"Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol: WJG. 2015;21(21):6518.","journal-title":"World J Gastroenterol: WJG"},{"issue":"4","key":"1189_CR63","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2013.05.025","volume":"59","author":"R Golfieri","year":"2013","unstructured":"Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59(4):753\u201361.","journal-title":"J Hepatol"},{"issue":"6","key":"1189_CR64","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/cancers12061557","volume":"12","author":"E Garin","year":"2020","unstructured":"Garin E, Palard X, Rolland Y. Personalised dosimetry in radioembolisation for HCC: impact on clinical outcome and on trial design. Cancers. 2020;12(6):1557.","journal-title":"Cancers"},{"issue":"1","key":"1189_CR65","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192\u2013201.","journal-title":"Hepatology"},{"issue":"21","key":"1189_CR66","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","volume":"21","author":"Y Chang","year":"2020","unstructured":"Chang Y, Jeong SW, Young Jang J, Jae KY. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21):8165.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1189_CR67","first-page":"e190024","volume":"2","author":"M Mendiratta-Lala","year":"2020","unstructured":"Mendiratta-Lala M, Masch WR, Shampain K, Zhang A, Jo AS, Moorman S, et al. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiol: Imaging Cancer. 2020;2(1):e190024.","journal-title":"Radiol: Imaging Cancer"},{"key":"1189_CR68","doi-asserted-by":"publisher","unstructured":"Vardar BU, Meram E, Karaoglu K, Liang M, Yu M, Laeseke P, et al. Radioembolization followed by transarterial chemoembolization in hepatocellular carcinoma. Cureus. 2022;14(4). https:\/\/doi.org\/10.7759\/cureus.23783.","DOI":"10.7759\/cureus.23783"},{"key":"1189_CR69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"J Llovet","year":"2021","unstructured":"Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01189-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T21:44:05Z","timestamp":1740951845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01189-w","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"73"}}